Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reduced prefrontal cortex response to own vs. unknown emotional infant faces in mothers with bipolar disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reward processing in major depressive disorder and prediction of treatment response - Neuropharm study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. PET-BIDS, an extension to the brain imaging data structure for positron emission tomography

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Neuronal underpinnings of cognitive impairment in bipolar disorder: A large data-driven functional magnetic resonance imaging study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Psilocybin has in some studies shown promise as treatment of major depressive disorder and psilocybin therapy was in 2019 twice designated as breakthrough therapy by the U.S. Food and Drug Administration (FDA). A very particular feature is that ingestion of just a single dose of psilocybin is associated with lasting changes in personality and mood. The underlying molecular mechanism behind its effect is, however, unknown. In a translational pig model, we here present the effects of a single dose of psilocybin on pig behaviour, receptor occupancy and gene expression in the brain. An acute i.v. injection of 0.08 mg/kg psilocybin to awake female pigs induced characteristic behavioural changes in terms of headshakes, scratching and rubbing, lasting around 20 min. A similar dose was associated with a cerebral 5-HT2A receptor occupancy of 67%, as determined by positron emission tomography, and plasma psilocin levels were comparable to what in humans is associated with an intense psychedelic experience. We found that 19 genes were differentially expressed in prefrontal cortex one day after psilocybin injection, and 3 genes after 1 week. Gene Set Enrichment Analysis demonstrated that multiple immunological pathways were regulated 1 week after psilocybin exposure. This provides a framework for future investigations of the lasting molecular mechanisms induced by a single dose of psilocybin. In the light of an ongoing debate as to whether psilocybin is a safe treatment for depression and other mental illnesses, it is reassuring that our data suggest that any effects on gene expression are very modest.

Original languageEnglish
JournalEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Volume42
Pages (from-to)1-11
Number of pages11
ISSN0924-977X
DOIs
Publication statusPublished - Jan 2021

    Research areas

  • 5-HT receptor, Behaviour, Brain, Gene expression, Immune response, Psychedelic

ID: 62236746